SANOFI-ADR (NASDAQ:SNY) stands out as a compelling dividend stock, selected by our Best Dividend screen for its high dividend rating, strong profitability, and reasonable financial health. The company’s stable business model and consistent dividend payments make it an attractive option for income-focused investors.
Key Strengths
Dividend Performance: SNY offers a solid 4.09% dividend yield, outperforming 95.45% of its pharmaceutical industry peers. The company has maintained dividend payments for at least 10 years, demonstrating reliability. While the dividend growth rate is modest at 4.34%, the payout ratio of 39.72% indicates sustainability, as earnings comfortably cover distributions.
Profitability: With a Profitability Rating of 8/10, SNY excels in key financial metrics. Its Return on Equity (15.37%) and Return on Invested Capital (15.58%) rank above most industry competitors. Operating margins (22.04%) and profit margins (12.97%) are also strong, reinforcing efficient operations.
Valuation: SNY appears reasonably priced with a P/E ratio of 13.84, below the industry average (18.80) and the S&P 500 (24.29). Its forward P/E of 10.20 suggests further upside potential.
Financial Health: The company maintains a Health Rating of 5/10, with manageable debt levels (Debt/Equity of 0.17) and positive cash flow. However, liquidity metrics like the Quick Ratio (0.74) are weaker, warranting some caution.
Growth Outlook
While past earnings growth has been modest (5.10% annual EPS growth over five years), analysts expect an 8.23% EPS growth in the coming years. Revenue growth is projected at 4.33%, indicating steady expansion.
For a deeper analysis, review the full fundamental report on SNY.
Our Best Dividend Stocks screener provides more high-quality dividend stock ideas.
Disclaimer
This is not investment advice. Always conduct your own research before making investment decisions.